Relationship between the Monocyte Chemo-attractant Protein-1 gene rs1024611 A>G Polymorphism and Cancer Susceptibility: A Meta-analysis Involving 14,617 Subjects

References

• Ajuebor MN, Flower RJ, Hannon R, Christie M, Bowers K, Verity A, Perretti M. 1998. Endogenous monocyte chemoattractant protein-1 recruits monocytes in the zymosan peritonitis model. J Leukoc Biol. 63:108–16.
   PubMed Web of Science ®Google Scholar
• Attar R, Agachan B, Kuran SB, Cacina C, Sozen S, Yurdum LM, Attar E, Isbir T. 2010. Association of CCL2 and CCR2 gene variants with endometrial cancer in Turkish women. In Vivo. 24:243–48.
   PubMed Web of Science ®Google Scholar
• Bektas-Kayhan K, Unur M, Boy-Metin Z, Cakmakoglu B. 2012. MCP-1 and CCR2 gene variants in oral squamous cell carcinoma. Oral Dis. 18:55–59.
   PubMed Web of Science ®Google Scholar
• Bilen MA, Martini DJ, Liu Y, Lewis C, Collins HH, Shabto JM, Akce M, Kissick HT, Carthon BC, Shaib WL, et al. 2019. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer. 125:127–34.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424.
   PubMed Web of Science ®Google Scholar
• Brummer G, Acevedo DS, Hu Q, Portsche M, Fang WB, Yao M, Zinda B, Myers M, Alvarez N, Fields P, et al. 2018. Chemokine signaling facilitates early-stage breast cancer survival and invasion through fibroblast-dependent mechanisms. Mol Cancer Res. 16:296–308.
   PubMed Web of Science ®Google Scholar
• Chen MK, Yeh KT, Chiou HL, Lin CW, Chung TT, Yang SF. 2011. CCR2-64I gene polymorphism increase susceptibility to oral cancer. Oral Oncol. 47:577–82.
   PubMed Web of Science ®Google Scholar
• Da LS, Zhang Y, Zhang S, Qian YC, Zhang Q, Jiang F, Xu L. 2013. Association between MCP-1-2518A/G polymorphism and cancer risk: evidence from 19 case-control studies. PLoS One. 8:e82855.
   PubMedGoogle Scholar
• Daly C, Rollins BJ. 2003. Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic opportunities and controversies. Microcirculation. 10:247–57.
   PubMed Web of Science ®Google Scholar
• De la Fuente Lopez M, Landskron G, Parada D, Dubois-Camacho K, Simian D, Martinez M, Romero D, Roa JC, Chahuan I, Gutierrez R, et al. 2018. The relationship between chemokines CCL2, CCL3, and CCL4 with the tumor microenvironment and tumor-associated macrophage markers in colorectal cancer. Tumour Biol. 40:1010428318810059.
   Google Scholar
• DerSimonian R, Laird N. 1986. Meta-analysis in clinical trials. Control Clin Trials. 7:177–88.
   PubMed Web of Science ®Google Scholar
• Do HTT, Lee CH, Cho J. 2020. Chemokines and their receptors: multifaceted roles in cancer progression and potential value as cancer prognostic markers. Cancers. 12(2):287.
   PubMed Web of Science ®Google Scholar
• Giopanou I, Lilis I, Papaleonidopoulos V, Agalioti T, Kanellakis NI, Spiropoulou N, Spella M, Stathopoulos GT. 2017. Tumor-derived osteopontin isoforms cooperate with TRP53 and CCL2 to promote lung metastasis. Oncoimmunology. 6:e1256528.
   PubMed Web of Science ®Google Scholar
• Gong Z, Quan L, Yao S, Zirpoli G, Bandera EV, Roberts M, Coignet JG, Cabasag C, Sucheston L, Hwang H, et al. 2013. Innate immunity pathways and breast cancer Risk in African American and European-American women in the Women’s Circle of Health Study (WCHS). PLoS One. 8:e72619.
   PubMed Web of Science ®Google Scholar
• Gu H, Ni M, Guo X, Feng P, Xu Y, Gu X, Yang L, Wang B. 2011. The functional polymorphism in monocyte chemoattractant protein-1 gene increases susceptibility to gastric cancer. Med Oncol. 28(Suppl 1):S280–285.
   PubMedGoogle Scholar
• Handel TM, Domaille PJ. 1996. Heteronuclear (1H, 13C, 15N) NMR assignments and solution structure of the monocyte chemoattractant protein-1 (MCP-1) dimer. Biochemistry. 35:6569–84.
   PubMed Web of Science ®Google Scholar
• He S, Zhang X. 2018. The rs1024611 in the CCL2 gene and risk of gynecological cancer in Asians: a meta-analysis. World J Surg Oncol. 16:34.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. 2003. Measuring inconsistency in meta-analyses. Bmj. 327:557–60.
   PubMed Web of Science ®Google Scholar
• Hussain SP, Harris CC. 2007. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 121:2373–80.
   PubMed Web of Science ®Google Scholar
• Jia LQ, Shen YC, Guo SJ, Hu QJ, Pang CS, Wang T, Chen L, Wen FQ. 2013. The 2518 A/G polymorphism in the MCP-1 gene and cancer risk: a meta-analysis. APJCP. 14:3575–79.
   Google Scholar
• Jianing Q. 2009. Exploration on the relation between genetic polymorphism in TGF-β signaling pathway and hepatocellular carcinoma and nasopharyngeal carcinoma. Guangxi: Guangxi Medical Univesity.
   Google Scholar
• Jones SA, Jenkins BJ. 2018. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 18:773–89.
   PubMed Web of Science ®Google Scholar
• Joshi NN, Bhat S, Hake S, Kale M, Kannan S. 2014. Opposing effects of pro- and anti-inflammatory cytokine gene polymorphisms on the risk for breast cancer in western Indian women: a pilot study. Int J Immunogenet. 41:242–49.
   PubMed Web of Science ®Google Scholar
• Kersten K, Coffelt SB, Hoogstraat M, Verstegen NJM, Vrijland K, Ciampricotti M, Doornebal CW, Hau CS, Wellenstein MD, Salvagno C, et al. 2017. Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1beta in tumor-associated macrophages. Oncoimmunology. 6:e1334744.
   PubMed Web of Science ®Google Scholar
• Krasnikova TL, Arefieva TI, Pylaeva EA, Sidorova MV. 2016. Ingramon, a peptide inhibitor of MCP-1 Chemokine, reduces migration of blood monocytes stimulated by glioma-conditioned medium. Bull Exp Biol Med. 160:480–82.
   PubMed Web of Science ®Google Scholar
• Kruszyna L, Lianeri M, Rubis B, Knula H, Rybczynska M, Grodecka-Gazdecka S, Jagodzinski PP. 2011. CCL2-2518 A/G single nucleotide polymorphism as a risk factor for breast cancer. Mol Biol Rep. 38:1263–67.
   PubMed Web of Science ®Google Scholar
• Ksiazek K, Buraczynska M. 2019. Association between monocyte chemoattractant protein-1-2518 (A/G) single nucleotide polymorphism and chronic periodontitis in end-stage renal disease patients - a case-control study. Immunol Invest. 1–10. doi:10.1080/08820139.2019.1702052
   PubMed Web of Science ®Google Scholar
• Kucukgergin C, Isman FK, Cakmakoglu B, Sanli O, Seckin S. 2012a. Association of polymorphisms in MCP-1, CCR2, and CCR5 genes with the risk and clinicopathological characteristics of prostate cancer. DNA Cell Biol. 31:1418–24.
   PubMed Web of Science ®Google Scholar
• Kucukgergin C, Isman FK, Dasdemir S, Cakmakoglu B, Sanli O, Gokkusu C, Seckin S. 2012b. The role of chemokine and chemokine receptor gene variants on the susceptibility and clinicopathological characteristics of bladder cancer. Gene. 511:7–11.
   PubMed Web of Science ®Google Scholar
• Landi S, Gemignani F, Bottari F, Gioia-Patricola L, Guino E, Cambray M, Biondo S, Capella G, Boldrini L, Canzian F, et al. 2006. Polymorphisms within inflammatory genes and colorectal cancer. J Negat Results Biomed. 5:15.
   PubMedGoogle Scholar
• Li L, Liu YD, Zhan YT, Zhu YH, Li Y, Xie D, Guan XY. 2018. High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma. Thorac Cancer. 9:775–84.
   PubMed Web of Science ®Google Scholar
• Li L, Zhang J, Weng X, Wen G. 2015. Genetic variations in monocyte chemoattractant protein-1 and susceptibility to ovarian cancer. Tumour Biol. 36:233–38.
   PubMedGoogle Scholar
• Liu B, Chen P, Xi D, Zhu H, Gao Y. 2017. ATF4 regulates CCL2 expression to promote endometrial cancer growth by controlling macrophage infiltration. Exp Cell Res. 360:105–12.
   PubMed Web of Science ®Google Scholar
• Liu GX, Zhang X, Li S, Koiiche RD, Sindsceii JH, Song H. 2013. Monocyte chemotactic protein-1 and CC chemokine receptor 2 polymorphisms and prognosis of renal cell carcinoma. Tumour Biol. 34:2741–46.
   PubMed Web of Science ®Google Scholar
• Mandal PK, Biswas S, Mandal G, Purohit S, Gupta A, Majumdar Giri A, Roy Chowdhury S, Bhattacharyya A. 2018. CCL2 conditionally determines CCL22-dependent Th2-accumulation during TGF-beta-induced breast cancer progression. Immunobiology. 223:151–61.
   PubMed Web of Science ®Google Scholar
• Mandal RK, Agrawal T, Mittal RD. 2015. Genetic variants of chemokine CCL2 and chemokine receptor CCR2 genes and risk of prostate cancer. Tumour Biol. 36:375–81.
   PubMedGoogle Scholar
• Mantel N,HW. 1959. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:719–48.
   PubMed Web of Science ®Google Scholar
• Matsushima K, Larsen CG, DuBois GC, Oppenheim JJ. 1989. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med. 169:1485–90.
   PubMed Web of Science ®Google Scholar
• Merle M, Fischbacher D, Liepert A, Grabrucker C, Kroell T, Kremser A, Dreyssig J, Freudenreich M, Schuster F, Borkhardt A, et al. 2020. Serum Chemokine-release profiles in AML-patients might contribute to predict the clinical course of the disease. Immunol Invest. 49:365–85.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 151:264–69. W264. doi:10.7326/0003-4819-151-4-200908180-00135.
   PubMed Web of Science ®Google Scholar
• Nagarsheth N, Wicha MS, Zou W. 2017. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 17:559–72.
   PubMed Web of Science ®Google Scholar
• Narter KF, Agachan B, Sozen S, Cincin ZB, Isbir T. 2010. CCR2-64I is a risk factor for development of bladder cancer. GMR. 9:685–92.
   PubMed Web of Science ®Google Scholar
• Niu Y, Zhou G, Wang Y, Qin J, Ping J, Zhang Q, Han BW, Liu YX, Yang C, Zhai Y, et al. 2019. Association of MCP-1 promoter polymorphism with susceptibility to nasopharyngeal carcinoma. J Cell Biochem. 120:6661–70.
   PubMed Web of Science ®Google Scholar
• Pham MH, Bonello GB, Castiblanco J, Le T, Sigala J, He W, Mummidi S. 2012. The rs1024611 regulatory region polymorphism is associated with CCL2 allelic expression imbalance. PLoS One. 7:e49498.
   PubMedGoogle Scholar
• Qiu H, Cheng C, Wang Y, Kang M, Tang W, Chen S, Gu H, Liu C, Chen Y. 2016. Investigation of cyclin D1 rs9344 G>A polymorphism in colorectal cancer: a meta-analysis involving 13,642 subjects. Onco Targets Ther. 9:6641–50.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Nicolas A, Jiménez P, Carmona FD, Martín J, Matas Cobos AM, Ruiz-Cabello F, Redondo-Cerezo E. 2019. Association between genetic polymorphisms of inflammatory response genes and acute pancreatitis. Immunol Invest. 48:585–96.
   PubMed Web of Science ®Google Scholar
• Rollins BJ, Morton CC, Ledbetter DH, Eddy RL, Shows TB. 1991. Assignment of the human small inducible cytokine A2 gene, SCYA2 (encoding JE or MCP-1), to 17q11.2–12: evolutionary relatedness of cytokines clustered at the same locus. Genomics. 10:489–92.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Lu L, Saxena R. 1999. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun. 259:344–48.
   PubMed Web of Science ®Google Scholar
• Saenz-Lopez P, Carretero R, Cozar JM, Romero JM, Canton J, Vilchez JR, Tallada M, Garrido F, Ruiz-Cabello F. 2008. Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer. 8:382.
   PubMed Web of Science ®Google Scholar
• Sambyal V, Guleria K, Kapahi R, Manjari M, Sudan M, Uppal MS, Singh NR. 2015. Association of the −2518 A/G polymorphism of MCP-1 with breast cancer in Punjab, North-West India. APJCP. 16:7243–48.
   Google Scholar
• Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, Mitchem JB, Plambeck-Suess SM, Worley LA, Goetz BD, et al. 2013. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res. 19:3404–15.
   PubMed Web of Science ®Google Scholar
• Singh V, Srivastava P, Srivastava N, Kapoor R, Mittal RD. 2012a. Association of inflammatory chemokine gene CCL2I/D with bladder cancer risk in North Indian population. Mol Biol Rep. 39:9827–34.
   PubMed Web of Science ®Google Scholar
• Singh V, Srivastava P, Srivastava N, Kapoor R, Mittal RD. 2012b. Association of inflammatory chemokine gene CCL2I/D with bladder cancer risk in North Indian populatiopn. Mol Biol Rep. 39:9827–34.
   PubMed Web of Science ®Google Scholar
• Sobjanek M, Zablotna M, Szczerkowska-Dobosz A, Ruckemann-Dziurdzinska K, Sokolowska-Wojdylo M, Nowicki R. 2016. -2518 A/G MCP-1 but not −403 G/A RANTES gene polymorphism is associated with enhanced risk of basal cell carcinoma. Postepy Dermatologii I Alergologii. 33:381–85.
   PubMed Web of Science ®Google Scholar
• Soria G, Ben-Baruch A. 2008. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 267:271–85.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Galligan C, Tessarollo L, Yoshimura T. 2009. Monocyte chemoattractant protein-1 (MCP-1), not MCP-3, is the primary chemokine required for monocyte recruitment in mouse peritonitis induced with thioglycollate or zymosan A. J Immunol. 183:3463–71.
   PubMed Web of Science ®Google Scholar
• Tang W, Wang Y, Jiang H, Liu P, Liu C, Gu H, Chen S, Kang M. 2015. Programmed death-1 (PD-1) rs2227981 C > T polymorphism is associated with cancer susceptibility: a meta-analysis. Int J Clin Exp Med. 8:22278–85.
   PubMedGoogle Scholar
• Thames AD, Briones MS, Magpantay LI, Martinez-Maza O, Singer EJ, Hinkin CH, Morgello S, Gelman BB, Moore DJ, Heizerling K, et al. 2015. The role of chemokine C-C motif ligand. 2 genotype and cerebrospinal fluid chemokine C-C motif ligand 2 in neurocognition among HIV-infected patients. AIDS (London, England). 29:1483–91.
   PubMed Web of Science ®Google Scholar
• Tomic T, Dominguez-Lopez S, Barrios-Rodriguez R. 2019. Non-aspirin non-steroidal anti-inflammatory drugs in prevention of colorectal cancer in people aged 40 or older: A systematic review and meta-analysis. Cancer Epidemiol. 58:52–62.
   PubMed Web of Science ®Google Scholar
• Torre LA, Siegel RL, Ward EM, Jemal A. 2016. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiology, Biomarkers Prev. 25:16–27. doi:10.1158/1055-9965.EPI-15-0578
   Google Scholar
• Van Coillie E, Van Damme J, Opdenakker G. 1999. The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev. 10:61–86.
   PubMed Web of Science ®Google Scholar
• Vazquez-Lavista LG, Lima G, Gabilondo F, Llorente L. 2009. Genetic Association of Monocyte Chemoattractant Protein 1 (MCP-1)-2518 Polymorphism in Mexican Patients With Transitional Cell Carcinoma of the Bladder. Urology. 74(2):414–18.
   PubMed Web of Science ®Google Scholar
• Walczak A, Przybylowska-Sygut K, Sygut A, Cieslak A, Mik M, Dziki L, Dziki A, Majsterek I. 2017. An association of the MCP-1 and CCR2 single nucleotide polymorphisms with colorectal cancer prevalence. Pol Przegl Chir. 89:1–5.
   PubMedGoogle Scholar
• Wang T, Zhan Q, Peng X, Qiu Z, Zhao T. 2018a. CCL2 influences the sensitivity of lung cancer A549 cells to docetaxel. Oncol Lett. 16:1267–74.
   PubMed Web of Science ®Google Scholar
• Wang W, Shen F, Wang C, Lu W, Wei J, Shang A, Wang C. 2017. MiR-1-3p inhibits the proliferation and invasion of bladder cancer cells by suppressing CCL2 expression. Tumour Biol. 39:1010428317698383.
   Google Scholar
• Wang Y, Zhang X, Yang L, Xue J, Hu G. 2018b. Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer. J Bone Oncol. 11:27–32.
   PubMed Web of Science ®Google Scholar
• Wei X, Tian Y, Lu W, Li W, Zhang M, Lu X, Liu Y. 2015. Functional polymorphisms in monocyte chemoattractant protein-1 are associated with increased susceptibility to ovarian cancer. DNA Cell Biol. 34:37–42.
   PubMed Web of Science ®Google Scholar
• Wu HH, Lee TH, Tee YT, Chen SC, Yang SF, Lee SK, Ko JL, Wang PH. 2013. Relationships of single nucleotide polymorphisms of monocyte chemoattractant protein 1 and chemokine receptor 2 with susceptibility and clinicopathologic characteristics of neoplasia of uterine cervix in Taiwan women. Reprod Sci. 20:1175–83.
   PubMed Web of Science ®Google Scholar
• Yang L, Shi GL, Song CX, Xu SF. 2010. Relationship between genetic polymorphism of MCP-1 and non-small-cell lung cancer in the Han nationality of North China. GMR. 9:765–71.
   PubMed Web of Science ®Google Scholar
• Yang L, Wang J, Li FG, Han M, Chang XJ, Wang ZT. 2015. Relationship between genetic polymorphisms in MCP-1, CCR-2, and non-small-cell lung cancer in the Han nationality of Northern China. GMR. 14:3745–52.
   PubMed Web of Science ®Google Scholar
• Yao M, Fang W, Smart C, Hu Q, Huang S, Alvarez N, Fields P, Cheng N. 2019. CCR2 Chemokine receptors enhance growth and cell-cycle progression of breast cancer cells through SRC and PKC activation. Mol Cancer Res. 17:604–17.
   PubMed Web of Science ®Google Scholar
• Yasui H, Kajiyama H, Tamauchi S, Suzuki S, Peng Y, Yoshikawa N, Sugiyama M, Nakamura K, Kikkawa F. 2020. CCL2 secreted from cancer-associated mesothelial cells promotes peritoneal metastasis of ovarian cancer cells through the P38-MAPK pathway. Clin Exp Metastasis. 37:145–58.
   PubMed Web of Science ®Google Scholar
• Yeh CB, Tsai HT, Chen YC, Kuo WH, Chen TY, Hsieh YH, Chou MC, Yang SF. 2010. Genetic polymorphism of CCR2-64I increased the susceptibility of hepatocellular carcinoma. J Surg Oncol. 102:264–70.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yan Y, Cui X, Zhang J, Yang Y, Li H, Wu H, Li J, Wang L, Li M, et al. 2017. CCL2 expression correlates with Snail expression and affects the prognosis of patients with gastric cancer. Pathol Res Pract. 213:217–21.
   PubMed Web of Science ®Google Scholar
• Zhuang H, Cao G, Kou C, Liu T. 2018. CCL2/CCR2 axis induces hepatocellular carcinoma invasion and epithelial-mesenchymal transition in vitro through activation of the Hedgehog pathway. Oncol Rep. 39:21–30.
   PubMed Web of Science ®Google Scholar